静脉血管活性肠肽(阿维普地尔)治疗重症COVID-19呼吸衰竭:60天随机对照试验结果
这项多中心、安慰剂对照试验纳入196例COVID-19呼吸衰竭患者,按2:1随机接受3天静脉阿维普地尔或安慰剂。预设校正基线通气状态后,主要终点(60天存活且无呼吸衰竭)未达统计学显著(OR 1.6,95%CI 0.86-3.11)。60天生存胜算比显著提高(OR 2.0,95%CI 1.1-3.9,P=0.035),第3天呼吸窘迫比率改善及白介素6释放减少(P=0.02)。基线高流量鼻导管氧疗亚组主要终点显著(P=0.039),机械通气亚组生存胜算比提高10倍(P=0.031)。作者认为获益风险比有利。
要点
- 主要终点(60天存活且无呼吸衰竭)未达统计学显著:OR 1.6(95%CI 0.86-3.11),校正基线通气状态。
- 60天生存胜算比显著提高:OR 2.0(95%CI 1.1-3.9,P=0.035)。
- 第3天呼吸窘迫比率改善、白介素6释放减少(P=0.02)。
- 基线高流量鼻导管氧疗亚组主要终点显著(P=0.039);机械通气亚组生存胜算比提高10倍(P=0.031)。
- 无药物相关严重不良事件,安全性可接受;作者认为获益风险比有利。
适用人群与场景
- 196例COVID-19呼吸衰竭患者,来自美国10家医院(6家三级医院、4家社区医院)。
处置流程与药物剂量
- 参与者按2:1随机接受3天静脉阿维普地尔或安慰剂。
研究设计与关键结果
- 多中心、安慰剂对照试验,纳入196例COVID-19呼吸衰竭患者,随机2:1接受3天静脉阿维普地尔或安慰剂。
- 主要终点(60天存活且无呼吸衰竭)未达统计学显著:OR 1.6(95%CI 0.86-3.11),预设校正基线通气状态。
- 60天生存胜算比显著提高:OR 2.0(95%CI 1.1-3.9,P=0.035)。
- 第3天呼吸窘迫比率改善、白介素6释放减少(P=0.02)。
- 基线高流量鼻导管氧疗亚组主要终点显著(P=0.039);机械通气亚组生存胜算比提高10倍(P=0.031)。
- 无药物相关严重不良事件。
证据类型、等级与局限
- 多中心、安慰剂对照随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,鉴于无药物相关严重不良事件且安全性可接受,阿维普地尔获益风险比有利,可用于患者治疗。
- 主要终点未达统计学显著,提示阿维普地尔与安慰剂无差异;但60天生存胜算比提高,尤其机械通气亚组生存胜算比提高10倍(P=0.031)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy. Vasoactive intestinal peptide (VIP) is shown in nonclinical studies to upregulate surfactant production, inhibit cytokine synthesis, prevent cytopathy, and block replication of the severe acute respiratory syndrome coronavirus 2 virus in pulmonary cells. The study aims to determine whether Aviptadil (synthetic VIP) can improve survival and recovery in patients with COVID-19 respiratory failure compared with placebo and demonstrate biological effects in such patients.
DESIGN: A multicenter, placebo-controlled trial.
SETTING: Ten U.S. hospitals: six tertiary-care hospitals and four community hospitals.
PATIENTS: A total of 196 patients with COVID-19 respiratory failure.
INTERVENTIONS: Participants were randomized 2:1 to receive 3 days of IV Aviptadil or placebo.
MEASUREMENTS AND MAIN RESULTS: The primary end point (alive and free from respiratory failure at day 60) did not reach statistical significance (odds ratio [OR], 1.6; 95% CI, 0.86-3.11) for patients treated with Aviptadil when controlling for baseline ventilation status as prespecified in the protocol. There was, however, a statistically significant two-fold odds of improved survival (OR, 2.0; 95% CI, 1.1-3.9) at 60 days ( p = 0.035). There was significant improvement in respiratory distress ratio and reduced interleukin 6 cytokine release ( p = 0.02) by day 3.Subgroup analysis identified a statistically significant likelihood of achieving primary end point among those treated with high-flow nasal oxygen at baseline ( p = 0.039). Subjects on mechanical ventilation also experienced a 10-fold increased odds of survival with drug versus placebo ( p = 0.031).
CONCLUSIONS: The primary end point did not reach statistical significance, indicating that there was no difference between Aviptadil versus placebo. However, Aviptadil improves the likelihood of survival from respiratory failure at day 60 in critical COVID-19 across all sites of care. Given the absence of drug-related serious adverse events and acceptable safety profile, we believe the benefit versus risk for the use of Aviptadil is favorable for patient treatment.
参考来源
- Youssef JG, Lavin P, Schoenfeld DA, et al. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial. Crit Care Med. 2022. PMID: 36044317. doi:10.1097/CCM.0000000000005660
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。